{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:51:11Z","timestamp":1794621071189,"version":"4.9.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR071463"],"award-info":[{"award-number":["AR071463"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is well-established that receptor activator of NF-\u03baB ligand (RANKL) is the inducer of physiological osteoclast differentiation. However, the specific drivers and mechanisms driving inflammatory osteoclast differentiation under pathological conditions remain obscure. This is especially true given that inflammatory cytokines such as tumor necrosis factor (TNF) demonstrate little to no ability to directly drive osteoclast differentiation. Here, we found that transforming growth factor \u03b2 (TGF\u03b2) priming enables TNF to effectively induce osteoclastogenesis, independently of the canonical RANKL pathway. Lack of TGF\u03b2 signaling in macrophages suppresses inflammatory, but not basal, osteoclastogenesis and bone resorption in vivo. Mechanistically, TGF\u03b2 priming reprograms the macrophage response to TNF by remodeling chromatin accessibility and histone modifications, and enables TNF to induce a previously unrecognized non-canonical osteoclastogenic program, which includes suppression of the TNF-induced IRF1-IFN\u03b2-IFN-stimulated-gene axis, IRF8 degradation and B-Myb induction. These mechanisms are active in rheumatoid arthritis, in which TGF\u03b2 level is elevated and correlates with osteoclast activity. Our findings identify a TGF\u03b2\/TNF-driven inflammatory osteoclastogenic program, and may lead to development of selective treatments for inflammatory osteolysis.<\/jats:p>","DOI":"10.1038\/s41467-022-31475-1","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:04:03Z","timestamp":1657195443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["TGF\u03b2 reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis"],"prefix":"10.1038","volume":"13","author":[{"given":"Yuhan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-6249","authenticated-orcid":false,"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Premkumar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-8532","authenticated-orcid":false,"given":"Matthew B.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-0919","authenticated-orcid":false,"given":"Baohong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"31475_CR1","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/rheumatology\/keg327","volume":"42","author":"SR Goldring","year":"2003","unstructured":"Goldring, S. R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 42, ii11\u2013ii16 (2003).","journal-title":"Rheumatology"},{"key":"31475_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev.pathmechdis.3.121806.151431","volume":"3","author":"DV Novack","year":"2008","unstructured":"Novack, D. V. & Teitelbaum, S. L. The osteoclast: friend or foe? Annu Rev. Pathol. 3, 457\u2013484 (2008).","journal-title":"Annu Rev. Pathol."},{"key":"31475_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.bor.0000231912.24740.a5","volume":"18","author":"K Sato","year":"2006","unstructured":"Sato, K. & Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419\u2013426 (2006).","journal-title":"Curr. Opin. Rheumatol."},{"key":"31475_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1196\/annals.1402.084","volume":"1116","author":"BF Boyce","year":"2007","unstructured":"Boyce, B. F. et al. New roles for osteoclasts in bone. Ann. N.Y Acad. Sci. 1116, 245\u2013254 (2007).","journal-title":"Ann. N.Y Acad. Sci."},{"key":"31475_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat. Rev. Rheumatol. 8, 656\u2013664 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"31475_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/ar1857","volume":"8","author":"SL Teitelbaum","year":"2006","unstructured":"Teitelbaum, S. L. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res. Ther. 8, 201 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"31475_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrrheum.2009.175","volume":"5","author":"Y Choi","year":"2009","unstructured":"Choi, Y., Arron, J. R. & Townsend, M. J. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 543\u2013548 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"31475_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri3834","volume":"15","author":"D Brenner","year":"2015","unstructured":"Brenner, D., Blaser, H. & Mak, T. W. Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15, 362\u2013374 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"31475_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias, G. D. & Ivashkiv, L. B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12, 49\u201362 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"31475_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1359\/jbmr.090533","volume":"24","author":"G Schett","year":"2009","unstructured":"Schett, G. & Teitelbaum, S. L. Osteoclasts and arthritis. J. Bone Miner. Res. 24, 1142\u20131146 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"31475_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-0-387-89520-8_3","volume":"647","author":"G Sethi","year":"2009","unstructured":"Sethi, G., Sung, B., Kunnumakkara, A. B. & Aggarwal, B. B. Targeting TNF for treatment of cancer and autoimmunity. Adv. Exp. Med. Biol. 647, 37\u201351 (2009).","journal-title":"Adv. Exp. Med. Biol."},{"key":"31475_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578\u2013582 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"31475_CR13","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange, U., Teichmann, J., Muller-Ladner, U. & Strunk, J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology 44, 1546\u20131548 (2005).","journal-title":"Rheumatology"},{"key":"31475_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2008.091611","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts, C. A. et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann. Rheum. Dis. 68, 373\u2013376 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"31475_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/01.bor.0000231913.32364.32","volume":"18","author":"BF Boyce","year":"2006","unstructured":"Boyce, B. F., Schwarz, E. M. & Xing, L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr. Opin. Rheumatol. 18, 427\u2013432 (2006).","journal-title":"Curr. Opin. Rheumatol."},{"key":"31475_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam, J. et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Investig. 106, 1481\u20131488 (2000).","journal-title":"J. Clin. Investig."},{"key":"31475_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1084\/jem.20050978","volume":"202","author":"N Kim","year":"2005","unstructured":"Kim, N. et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202, 589\u2013595 (2005).","journal-title":"J. Exp. Med."},{"key":"31475_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.191.2.275","volume":"191","author":"K Kobayashi","year":"2000","unstructured":"Kobayashi, K. et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction. J. Exp. Med. 191, 275\u2013286 (2000).","journal-title":"J. Exp. Med."},{"key":"31475_CR19","doi-asserted-by":"publisher","first-page":"583561","DOI":"10.3389\/fendo.2020.583561","volume":"11","author":"B Zhao","year":"2020","unstructured":"Zhao, B. Intrinsic restriction of TNF-mediated inflammatory osteoclastogenesis and bone resorption. Front. Endocrinol. 11, 583561 (2020).","journal-title":"Front. Endocrinol."},{"key":"31475_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/17453674.2013.859423","volume":"85","author":"P Aspenberg","year":"2014","unstructured":"Aspenberg, P. Denosumab and atypical femoral fractures. Acta Orthop. 85, 1 (2014).","journal-title":"Acta Orthop."},{"key":"31475_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/clr.12556","volume":"27","author":"A Boquete-Castro","year":"2016","unstructured":"Boquete-Castro, A., Gomez-Moreno, G., Calvo-Guirado, J. L., Aguilar-Salvatierra, A. & Delgado-Ruiz, R. A. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin. Oral Implants Res. 27, 367\u2013375 (2016).","journal-title":"Clin. Oral Implants Res."},{"key":"31475_CR22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp, A. W., Zysset, P. K. & Lippuner, K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos. Int. 27, 1917\u20131921 (2016).","journal-title":"Osteoporos. Int."},{"key":"31475_CR23","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese, E. M. & Goldring, S. R. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 43, 2143\u20132151 (2000).","journal-title":"Arthritis Rheum."},{"key":"31475_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.1780390307","volume":"39","author":"F Eggelmeijer","year":"1996","unstructured":"Eggelmeijer, F. et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39, 396\u2013402 (1996).","journal-title":"Arthritis Rheum."},{"key":"31475_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/ard.51.6.761","volume":"51","author":"A Sileghem","year":"1992","unstructured":"Sileghem, A., Geusens, P. & Dequeker, J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann. Rheum. Dis. 51, 761\u2013764 (1992).","journal-title":"Ann. Rheum. Dis."},{"key":"31475_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar305","volume":"3","author":"Q Rehman","year":"2001","unstructured":"Rehman, Q. & Lane, N. E. Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res. 3, 221\u2013227 (2001).","journal-title":"Arthritis Res."},{"key":"31475_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/ard.2006.057497","volume":"66","author":"G Cohen","year":"2007","unstructured":"Cohen, G. et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann. Rheum. Dis. 66, 358\u2013363 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"31475_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.11481","volume":"50","author":"ET Molenaar","year":"2004","unstructured":"Molenaar, E. T. et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50, 36\u201342 (2004).","journal-title":"Arthritis Rheum."},{"key":"31475_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fimmu.2019.00679","volume":"10","author":"F Coury","year":"2019","unstructured":"Coury, F., Peyruchaud, O. & Machuca-Gayet, I. Osteoimmunology of bone loss in inflammatory rheumatic diseases. Front. Immunol. 10, 679 (2019).","journal-title":"Front. Immunol."},{"key":"31475_CR30","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/boneres.2016.9","volume":"4","author":"M Wu","year":"2016","unstructured":"Wu, M., Chen, G. & Li, Y. P. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 4, 16009 (2016).","journal-title":"Bone Res."},{"key":"31475_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"X Guo","year":"2009","unstructured":"Guo, X. & Wang, X. F. Signaling cross-talk between TGF-beta\/BMP and other pathways. Cell Res. 19, 71\u201388 (2009).","journal-title":"Cell Res."},{"key":"31475_CR32","doi-asserted-by":"crossref","unstructured":"Derynck R., Budi E. H. Specificity, versatility, and control of TGF-beta family signaling. Sci. Signal. 12, eaav5183 (2019).","DOI":"10.1126\/scisignal.aav5183"},{"key":"31475_CR33","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.4049\/jimmunol.165.8.4254","volume":"165","author":"T Kaneda","year":"2000","unstructured":"Kaneda, T. et al. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J. Immunol. 165, 4254\u20134263 (2000).","journal-title":"J. Immunol."},{"key":"31475_CR34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/jbmr.357","volume":"26","author":"T Yasui","year":"2011","unstructured":"Yasui, T. et al. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J. Bone Miner. Res. 26, 1447\u20131456 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"31475_CR35","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1359\/jbmr.2001.16.10.1787","volume":"16","author":"JM Quinn","year":"2001","unstructured":"Quinn, J. M. et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787\u20131794 (2001).","journal-title":"J. Bone Miner. Res."},{"key":"31475_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep35221","volume":"6","author":"M Morita","year":"2016","unstructured":"Morita, M. et al. Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. Sci. Rep. 6, 35221 (2016).","journal-title":"Sci. Rep."},{"key":"31475_CR37","doi-asserted-by":"publisher","first-page":"23397","DOI":"10.1074\/jbc.M109.019372","volume":"284","author":"N Houde","year":"2009","unstructured":"Houde, N., Chamoux, E., Bisson, M. & Roux, S. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J. Biol. Chem. 284, 23397\u201323404 (2009).","journal-title":"J. Biol. Chem."},{"key":"31475_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.imlet.2018.12.003","volume":"206","author":"B Lee","year":"2019","unstructured":"Lee, B., Oh, Y., Jo, S., Kim, T. H. & Ji, J. D. A dual role of TGF-beta in human osteoclast differentiation mediated by Smad1 versus Smad3 signaling. Immunol. Lett. 206, 33\u201340 (2019).","journal-title":"Immunol. Lett."},{"key":"31475_CR39","first-page":"155","volume":"14","author":"JF Schlaak","year":"1996","unstructured":"Schlaak, J. F., Pfers, I., Meyer Zum Buschenfelde, K. H. & Marker-Hermann, E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheumatol. 14, 155\u2013162 (1996).","journal-title":"Clin. Exp. Rheumatol."},{"key":"31475_CR40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1046\/j.1365-3083.1998.00399.x","volume":"48","author":"H Lettesjo","year":"1998","unstructured":"Lettesjo, H. et al. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand. J. Immunol. 48, 286\u2013292 (1998).","journal-title":"Scand. J. Immunol."},{"key":"31475_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/rheumatology\/36.1.38","volume":"36","author":"JD Canete","year":"1997","unstructured":"Canete, J. D. et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br. J. Rheumatol. 36, 38\u201342 (1997).","journal-title":"Br. J. Rheumatol."},{"key":"31475_CR42","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/art.1780330819","volume":"33","author":"P Miossec","year":"1990","unstructured":"Miossec, P., Naviliat, M., Dupuy d\u2019Angeac, A., Sany, J. & Banchereau, J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum. 33, 1180\u20131187 (1990).","journal-title":"Arthritis Rheum."},{"key":"31475_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/08916930902831977","volume":"42","author":"D Mieliauskaite","year":"2009","unstructured":"Mieliauskaite, D., Venalis, P., Dumalakiene, I., Venalis, A. & Distler, J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjogren\u2019s syndrome secondary to rheumatoid arthritis. Autoimmunity 42, 356\u2013358 (2009).","journal-title":"Autoimmunity"},{"key":"31475_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.169.1.291","volume":"169","author":"R Fava","year":"1989","unstructured":"Fava, R., Olsen, N., Keski-Oja, J., Moses, H. & Pincus, T. Active and latent forms of transforming growth factor beta activity in synovial effusions. J. Exp. Med. 169, 291\u2013296 (1989).","journal-title":"J. Exp. Med."},{"key":"31475_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00774-006-0725-9","volume":"25","author":"MG Sorensen","year":"2007","unstructured":"Sorensen, M. G. et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Miner. Metab. 25, 36\u201345 (2007).","journal-title":"J. Bone Miner. Metab."},{"key":"31475_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.immuni.2017.06.018","volume":"47","author":"K Murata","year":"2017","unstructured":"Murata, K. et al. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity 47, 66\u201379.e65 (2017).","journal-title":"Immunity"},{"key":"31475_CR47","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1172\/JCI26132","volume":"115","author":"H Kitaura","year":"2005","unstructured":"Kitaura, H. et al. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest 115, 3418\u20133427 (2005).","journal-title":"J. Clin. Invest"},{"key":"31475_CR48","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/416744a","volume":"416","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi, H. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416, 744\u2013749 (2002).","journal-title":"Nature"},{"key":"31475_CR49","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0092-8674(00)81989-3","volume":"87","author":"V Kouskoff","year":"1996","unstructured":"Kouskoff, V. et al. Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811\u2013822 (1996).","journal-title":"Cell"},{"key":"31475_CR50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/ni1576","volume":"9","author":"A Yarilina","year":"2008","unstructured":"Yarilina, A., Park-Min, K. H., Antoniv, T., Hu, X. & Ivashkiv, L. B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9, 378\u2013387 (2008).","journal-title":"Nat. Immunol."},{"key":"31475_CR51","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ni.3818","volume":"18","author":"SH Park","year":"2017","unstructured":"Park, S. H. et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nat. Immunol. 18, 1104\u20131116 (2017).","journal-title":"Nat. Immunol."},{"key":"31475_CR52","doi-asserted-by":"publisher","first-page":"21931","DOI":"10.1073\/pnas.1016071107","volume":"107","author":"MP Creyghton","year":"2010","unstructured":"Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931\u201321936 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31475_CR53","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1073\/pnas.0909344107","volume":"107","author":"R Karlic","year":"2010","unstructured":"Karlic, R., Chung, H. R., Lasserre, J., Vlahovicek, K. & Vingron, M. Histone modification levels are predictive for gene expression. Proc. Natl Acad. Sci. USA 107, 2926\u20132931 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31475_CR54","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. & Hata, A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug. Discov. 11, 790\u2013811 (2012).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"31475_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcdb.2014.01.009","volume":"32","author":"T Gaarenstroom","year":"2014","unstructured":"Gaarenstroom, T. & Hill, C. S. TGF-beta signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation. Semin. Cell Dev. Biol. 32, 107\u2013118 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"31475_CR56","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","volume":"40","author":"M Asagiri","year":"2007","unstructured":"Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251\u2013264 (2007).","journal-title":"Bone"},{"key":"31475_CR57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/ar3379","volume":"13","author":"B Zhao","year":"2011","unstructured":"Zhao, B. & Ivashkiv, L. B. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res. Ther. 13, 234 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"31475_CR58","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/nm.2007","volume":"15","author":"B Zhao","year":"2009","unstructured":"Zhao, B. et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15, 1066\u20131071 (2009).","journal-title":"Nat. Med."},{"key":"31475_CR59","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1073\/pnas.1315464111","volume":"111","author":"SJ Baker","year":"2014","unstructured":"Baker, S. J. et al. B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development. Proc. Natl. Acad. Sci. USA 111, 3122\u20133127 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31475_CR60","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/art.40476","volume":"70","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. Development of a molecular signature to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids. Arthritis Rheumatol. 70, 1331\u20131342 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"31475_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MD.0b013e3181632d18","volume":"87","author":"MB Santiago","year":"2008","unstructured":"Santiago, M. B. & Galvao, V. Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine 87, 37\u201344 (2008).","journal-title":"Medicine"},{"key":"31475_CR62","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ejim.2008.01.017","volume":"19","author":"C Pipili","year":"2008","unstructured":"Pipili, C., Sfritzeri, A. & Cholongitas, E. Deforming arthropathy in systemic lupus erythematosus. Eur. J. Intern. Med. 19, 482\u2013487 (2008).","journal-title":"Eur. J. Intern. Med."},{"key":"31475_CR63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/0961203311425528","volume":"21","author":"T Jin","year":"2012","unstructured":"Jin, T., Almehed, K., Carlsten, H. & Forsblad-d\u2019Elia, H. Decreased serum levels of TGF-beta1 are associated with renal damage in female patients with systemic lupus erythematosus. Lupus 21, 310\u2013318 (2012).","journal-title":"Lupus"},{"key":"31475_CR64","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3899\/jrheum.100180","volume":"37","author":"A Becker-Merok","year":"2010","unstructured":"Becker-Merok, A., Eilertsen, G. O. & Nossent, J. C. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 37, 2039\u20132045 (2010).","journal-title":"J. Rheumatol."},{"key":"31475_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1684\/ecn.2013.0331","volume":"24","author":"I Manolova","year":"2013","unstructured":"Manolova, I., Gerenova, J. & Ivanova, M. Serum levels of transforming growth factor-beta1 (TGF-beta1) in patients with systemic lupus erythematosus and Hashimoto\u2019s thyroiditis. Eur. Cytokine Netw. 24, 69\u201374 (2013).","journal-title":"Eur. Cytokine Netw."},{"key":"31475_CR66","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","volume":"97","author":"J Li","year":"2000","unstructured":"Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97, 1566\u20131571 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31475_CR67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00281-017-0619-z","volume":"39","author":"M Noack","year":"2017","unstructured":"Noack, M. & Miossec, P. Selected cytokine pathways in rheumatoid arthritis. Semin. Immunopathol. 39, 365\u2013383 (2017).","journal-title":"Semin. Immunopathol."},{"key":"31475_CR68","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1101\/gad.219626.113","volume":"27","author":"P Voigt","year":"2013","unstructured":"Voigt, P., Tee, W. W. & Reinberg, D. A double take on bivalent promoters. Genes Dev. 27, 1318\u20131338 (2013).","journal-title":"Genes Dev."},{"key":"31475_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315\u2013326 (2006).","journal-title":"Cell"},{"key":"31475_CR70","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/jcmm.12327","volume":"18","author":"S Salem","year":"2014","unstructured":"Salem, S. et al. A novel role for interferon regulatory factor 1 (IRF1) in regulation of bone metabolism. J. Cell. Mol. Med. 18, 1588\u20131598 (2014).","journal-title":"J. Cell. Mol. Med."},{"key":"31475_CR71","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nm.3774","volume":"21","author":"K Nishikawa","year":"2015","unstructured":"Nishikawa, K. et al. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nat. Med. 21, 281\u2013287 (2015).","journal-title":"Nat. Med."},{"key":"31475_CR72","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.4049\/jimmunol.1501466","volume":"196","author":"C Fang","year":"2016","unstructured":"Fang, C. et al. Cutting edge: EZH2 promotes osteoclastogenesis by epigenetic silencing of the negative regulator IRF8. J. Immunol. 196, 4452\u20134456 (2016).","journal-title":"J. Immunol."},{"key":"31475_CR73","doi-asserted-by":"crossref","unstructured":"Morikawa M., Derynck R., Miyazono K. TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb. Perspect. Biol. 8, a021873 (2016).","DOI":"10.1101\/cshperspect.a021873"},{"key":"31475_CR74","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello, D., Elez, E., Tabernero, J. & Seoane, J. Clinical development of therapies targeting TGFbeta: current knowledge and future perspectives. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 31, 1336\u20131349 (2020).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"31475_CR75","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res. 25, 1468\u20131486 (2010).","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res."},{"key":"31475_CR76","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/ni.2304","volume":"13","author":"H Xu","year":"2012","unstructured":"Xu, H. et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13, 642\u2013650 (2012).","journal-title":"Nat. Immunol."},{"key":"31475_CR77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"31475_CR78","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"31475_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"31475_CR80","doi-asserted-by":"publisher","first-page":"e10232","DOI":"10.1002\/btm2.10232","volume":"6","author":"G Matsumae","year":"2021","unstructured":"Matsumae, G. et al. Targeting thymidine phosphorylase as a potential therapy for bone loss associated with periprosthetic osteolysis. Bioeng. Transl. Med. 6, e10232 (2021).","journal-title":"Bioeng. Transl. Med."},{"key":"31475_CR81","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1093\/bioinformatics\/btr499","volume":"27","author":"A Kamburov","year":"2011","unstructured":"Kamburov, A., Cavill, R., Ebbels, T. M., Herwig, R. & Keun, H. C. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27, 2917\u20132918 (2011).","journal-title":"Bioinformatics"},{"key":"31475_CR82","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31475_CR83","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nmeth.4396","volume":"14","author":"MR Corces","year":"2017","unstructured":"Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959\u2013962 (2017).","journal-title":"Nat. Methods"},{"key":"31475_CR84","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"31475_CR85","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/nprot.2012.101","volume":"7","author":"J Feng","year":"2012","unstructured":"Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 7, 1728\u20131740 (2012).","journal-title":"Nat. Protoc."},{"key":"31475_CR86","unstructured":"Stark, R., Brown, G. DiffBind: differential binding analysis of ChIP-Seq peak data.\u00a0Bioconductor. http:\/\/bioconductor.org\/packages\/release\/bioc\/vignettes\/DiffBind\/inst\/doc\/DiffBind.pdf (2011)."},{"key":"31475_CR87","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ramirez","year":"2016","unstructured":"Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160\u2013W165 (2016).","journal-title":"Nucleic Acids Res."},{"key":"31475_CR88","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"31475_CR89","doi-asserted-by":"crossref","unstructured":"Skene P. J., Henikoff S. An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. eLife 6, e21856 (2017).","DOI":"10.7554\/eLife.21856"},{"key":"31475_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03081-7","volume":"9","author":"UK Sokhi","year":"2018","unstructured":"Sokhi, U. K. et al. Dissection and function of autoimmunity-associated TNFAIP3 (A20) gene enhancers in humanized mouse models. Nat. Commun. 9, 658 (2018).","journal-title":"Nat. Commun."},{"key":"31475_CR91","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307\u2013315 (2004).","journal-title":"Bioinformatics"},{"key":"31475_CR92","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31475-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:06:07Z","timestamp":1669295167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31475-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31475"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31475-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the given and family names of E. Premkumar Reddy were incorrectly structured. The name was displayed correctly in all versions at the time of publication. The original article has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3920"}}